Campus Science/Technology Officers Gain Stature

Where academic research and commercial enterprise converge, this new breed of college official serves as science's gatekeeper When Katharine Ku took on the directorship of the Office of Technology Licensing at Stanford University earlier this fall, she inherited quite a legacy from her predecessor, Neils Rimers. Her professional endowment included royalties totaling $25.6 million last year; a portfolio of patents and licenses that includes one of the most lucrative and commercially successful

Written bySusan L-J Dickinson
| 12 min read

Register for free to listen to this article
Listen with Speechify
0:00
12:00
Share

Her professional endowment included royalties totaling $25.6 million last year; a portfolio of patents and licenses that includes one of the most lucrative and commercially successful university patents to date; a faculty that is, as she puts it, "in the middle of Silicon Valley and immersed in the whole entrepreneurial culture"; and a staff of 20 to handle their inventions.

There are as many different paths to a position in technology transfer as there are facets to the job. A chemical engineer by training, Katharine Ku started her career as a patent engineer at Stanford University, helping investigators write descriptions of their inventions. After six years as associate director of technology licensing there, she left Stanford to become vice president of business development at Protein Design Labs Inc. in Palo Alto, Calif. It was from this biotech company that she was recruited back to Stanford this fall. Francis J. Meyer, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies